A small study of the RAS‑targeting drug daraxonrasib reported tumor shrinkage in over 30% of patients with KRAS‑mutated non‑small‑cell lung cancer.
A small study of the RAS‑targeting drug daraxonrasib reported tumor shrinkage in over 30% of patients with KRAS‑mutated non‑small‑cell lung cancer.